Federal Court Limits Access to Mifepristone, Impacting Abortion Services Nationwide

Court Ruling on Mifepristone Distribution

A federal appeals court has imposed restrictions on one of the most widely used abortion methods in the United States by prohibiting the mailing of mifepristone prescriptions. The unanimous decision from a three-judge panel of the 5th U.S. Circuit Court of Appeals in New Orleans mandates that the abortion pill must be dispensed only in person at clinics, countering regulations established by the federal Food and Drug Administration (FDA). This ruling, which is expected to be challenged in the U.S. Supreme Court, represents a significant shift in abortion policy following the 2022 Supreme Court decision that overturned Roe v. Wade, allowing states to enforce abortion bans.

Judge Kyle Duncan, appointed by former President Donald Trump, supported Louisiana's argument that permitting the drug to be mailed undermines the state's ban on abortions at any stage of pregnancy. The ruling states, 'Every abortion facilitated by FDA’s action cancels Louisiana’s ban on medical abortions and undermines its policy that ‘every unborn child is a human being from the moment of conception and is, therefore, a legal person.’

Mifepristone's Role in Abortions

Mifepristone is involved in most abortions in the US

Approved in 2000, mifepristone is recognized as a safe and effective method for terminating early pregnancies, often used alongside another medication, misoprostol. Research indicates that the majority of abortions in the U.S. are conducted using pills, with approximately 25% of abortions prescribed through telehealth services. A survey of abortion providers revealed that more women in states with abortion restrictions sought these services rather than traveling to states where abortion is permitted. Some Democratic-led states have enacted laws to protect providers who prescribe via telehealth to patients in restricted areas, which has led to increased scrutiny from abortion opponents targeting these medications through legislation and legal challenges.

Judicial Precedent and FDA Regulations

Ruling goes against how courts usually view FDA decisions

There is limited precedent for a federal court to override the FDA's scientific regulations, and it remains uncertain how swiftly or thoroughly this decision will affect the mailing of mifepristone across the country. Historically, judges have deferred to the FDA's assessments regarding drug safety and regulation. FDA officials under the Trump administration have indicated that a new review of mifepristone's safety is underway, directed by the president. The judges, all nominated by Republican presidents, acknowledged in their ruling that the FDA could not specify when this review would conclude and admitted it was still gathering data.

Due to rare instances of severe bleeding, the FDA initially enforced strict guidelines on who could prescribe and distribute mifepristone, allowing only specially certified physicians to do so after an in-person consultation. These requirements were lifted during the COVID-19 pandemic, with FDA officials under President Joe Biden asserting that after over two decades of monitoring mifepristone's use and reviewing numerous studies involving thousands of women, it was evident that women could safely use the pill without direct supervision. GenBioPro, the manufacturer of generic mifepristone, criticized the court's ruling, stating it disregards the FDA's rigorous scientific standards and decades of safe usage.

Wider Implications of the Ruling

The impact isn’t just in states with bans

In a legal filing, Louisiana's attorney general and a woman who claimed she was pressured into taking abortion pills requested that the FDA's regulations revert to the previous standards that required in-person prescriptions and dispensing. A federal judge in Louisiana ruled last month that these allowances undermined the state's abortion ban but did not immediately revoke the regulations. The recent ruling remains in effect as the case progresses through the courts and has implications beyond Louisiana and states with abortion restrictions. Telehealth prescriptions have become prevalent even in states where abortion is legal, and this ruling restricts access there as well.

Julia Kaye, an attorney with the ACLU, stated, 'This is going to affect patients’ access to abortion and miscarriage care in every state in the nation.' She emphasized that restrictions on telemedicine disproportionately impact rural communities, low-income individuals, people with disabilities, survivors of intimate partner violence, and communities of color. The National Right to Life Committee welcomed the ruling, asserting it reinstates essential oversight in women's health, with President Carol Tobias stating, 'Women deserve better than an abortion-by-mail system that prioritizes ideology over safety.'

Potential Supreme Court Appeal

Next step could be an appeal to the nation’s top court

This ruling sets the stage for a likely appeal to the Supreme Court. Louisiana Attorney General Liz Murrill expressed her commitment to defending women and children as the case unfolds. The conservative-majority Supreme Court previously overturned abortion as a nationwide right in 2022 but unanimously upheld access to mifepristone two years later. However, that 2024 decision sidestepped the core issues by ruling that the anti-abortion doctors involved did not have legal standing to sue. Representatives from the FDA and the U.S. Department of Justice did not respond immediately to requests for comments following the ruling. Meanwhile, anti-abortion advocates are celebrating the decision, with Marjorie Dannenfelser, president of Susan B. Anthony Pro-Life America, calling it 'a huge victory for victims and survivors of Biden’s reckless mail-order abortion drug regime.' She criticized the Trump administration for its slow review process, arguing that it has compelled states to take action, stating, 'Women and children suffer and state sovereignty is violated every day the FDA allows abortion drugs to flood the mail.'